Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from <scp>NHS</scp> England between 2013 and 2019

Catto, James W.F.; Mandrik, Olena; Quayle, Lewis A.; Hussain, Syed A.; McGrath, John; Cresswell, Joanne; Birtle, Alison; Jones, Rob; Mariappan, Paramananthan; Makaroff, Lydia; Knight, Allen; Mostafid, Hugh; Chilcott, Jim; Sasieni, Peter; Cumberbatch, Marcus

doi:10.1111/bju.15970

Cited by 13 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methods for this study are similar to previously published work using the NHS Digital (NHSD) database on the diagnosis, treatment, and survival trends for bladder, upper urinary tract, and urethral cancers [11].…”

Section: Methodsmentioning

confidence: 99%

Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019

et al. 2023

Self Cite

View full text Add to dashboard Cite

ObjectivesTo report the NHS Digital (NHSD) data for patients diagnosed with kidney cancer (KC) in England. We explore the incidence, route to diagnosis (RTD), treatment, and survival patterns from 2013 to 2019.Materials and MethodsData was extracted from the Cancer Data NHSD portal for International Classification of Diseases, 10th edition coded KC; this included Cancer Registry data, Hospital Episode Statistics, and cancer waiting times data.ResultsRegistrations included 66 696 individuals with KC. Incidence of new KC diagnoses increased (8998 in 2013, to 10 232 in 2019), but the age‐standardised rates were stable (18.7–19.4/100 000 population). Almost half of patients (30 340 [45.5%]) were aged 0–70 years and the cohort were most frequently diagnosed with Stage 1–2 KC (n = 26 297 [39.4%]). Most patients were diagnosed through non‐urgent general practitioner referrals (n = 16 814 [30.4%]), followed by 2‐week‐wait (n = 15 472 [28.0%]) and emergency routes (n = 11 796 [21.3%]), with older patients (aged ≥70 years), Stage 4 KCs, and patients with non‐specified renal cell carcinoma being significantly more likely to present through the emergency route (all P < 0.001). Invasive treatment (surgery or ablation), radiotherapy, or systemic anti‐cancer therapy use varied with disease stage, patient factors, and treatment network (Cancer Alliance). Survival outcomes differed by Stage, histological subtype, and social deprivation class (P < 0.001). Age‐standardised mortality rates did not change over the study duration, although immunotherapy usage is likely not captured in this study timeline.ConclusionThe NHSD resource provides useful insight about the incidence, diagnostic pathways, treatment, and survival of patients with KC in England and a useful benchmark for the upcoming commissioned National Kidney Cancer Audit. The RTD data may be limited by incidental diagnoses, which could confound the high proportion of ‘emergency’ diagnoses. Importantly, survival outcomes remained relatively unchanged.

show abstract

Section: Methodsmentioning

confidence: 99%

Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bladder cancer is a common malignancy that is an expensive cancer to treat [1]. In England, over 18,000 people are diagnosed with bladder cancer every year, of which approximately 25% are muscle-invasive bladder cancers (MIBCs) [2]. MIBC has a 50% 5-year survival rate despite radical surgery, radiotherapy and chemotherapy [3].…”

Section: Introductionmentioning

confidence: 99%

Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial

Griffin,

Down,

Quayle

et al. 2024

The Journal of Pathology CR

View full text Add to dashboard Cite

The GUSTO clinical trial (Gene expression subtypes of Urothelial carcinoma: Stratified Treatment and Oncological outcomes) uses molecular subtypes to guide neoadjuvant therapies in participants with muscle‐invasive bladder cancer (MIBC). Before commencing the GUSTO trial, we needed to determine the reliability of a commercial subtyping platform (Decipher Bladder; Veracyte) when performed in an external trial laboratory as this has not been done previously. Here, we report our pre‐trial verification of the TCGA molecular subtyping model using gene expression profiling. Formalin‐fixed paraffin‐embedded tissue blocks of MIBC were used for gene expression subtyping by gene expression microarrays. Intra‐ and inter‐laboratory technical reproducibilities, together with quality control of laboratory and bioinformatics processes, were assessed. Eighteen samples underwent analysis. RNA of sufficient quality and quantity was successfully extracted from all samples. All subtypes were represented in the cohort. Each sample was subtyped twice in our laboratory and once in a separate reference laboratory. No clinically significant discordance in subtype occurred between intra‐ or inter‐laboratory replicates. Examination of sample histopathology showed variability of morphological appearances within and between subtypes. Overall, these results show that molecular subtyping by gene expression profiling is reproducible, robust and suitable for use in the GUSTO clinical trial.

show abstract

“…Bladder cancer is a common malignancy and one of the most expensive to manage [1]. Over 128 000 individuals were diagnosed with bladder cancer in England between 2013 and 2019 [2]. The disease is best divided by stage into non‐muscle‐invasive (NMIBC) and muscle‐invasive (MIBC) bladder cancers.…”

Section: Introductionmentioning

confidence: 99%

Health‐related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year

Rogers,

Glaser,

Catto

et al. 2023

BJU International

Self Cite

View full text Add to dashboard Cite

ObjectivesTo describe the health‐related quality of life (HRQoL) of patients in a prospective 12‐month observational cohort study of new bladder cancer diagnoses and compare with national cancer and general population surveys.Patients and MethodsA prospective UK study in patients with new bladder cancer diagnoses at 13 NHS Trusts. The HRQoL data were collected at 3, 6, 9 and 12 months. Questionnaires used included: the EuroQoL five Dimensions (EQ‐5D), European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)‐30‐item core, EORTC QLQ‐24‐item non‐muscle‐invasive bladder cancer, and EORTC QLQ‐30‐item muscle‐invasive bladder cancer. Results were compared with the Cancer Quality of Life Survey and Health Survey for England.ResultsA total of 349 patients were recruited, 296 (85%) completed the first (baseline) and 233 (67%) the final survey. The patients underwent transurethral resection of bladder tumour (TURBT) ± intravesical therapy (238 patients, 80%), radical cystectomy/radiotherapy (51, 17%) or palliation (seven, 2%). At baseline, patients needing radical treatment reported worse HRQoL including lower social function (74.2 vs 83.8, P = 0.002), increased fatigue (31.5 vs 26.1, P = 0.03) and more future worries (39.2 vs 29.4, P = 0.005) than patients who underwent TURBT. Post‐treatment surveys showed no change/improvements for patients who underwent TURBT but deterioration for the radically treated cohort. At final survey, reports were similar to baseline, regardless of treatment. Radically treated patients continued to report poorer HRQoL including issues with body image (23.4 vs 12.5, P = 0.007) and male sexual function (75.8 vs 40.4, P < 0.001) compared to those who underwent TURBT. Radically treated patients reported lower EQ‐5D utility scores and more problems with usual activities than the general population.DiscussionPatients undergoing TURBT can be reassured regarding HRQoL following treatment. However, those requiring radical treatment report greater changes in HRQoL with the need for appropriate clinical and supportive care to minimise the impact of treatments.

show abstract

Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from NHS England between 2013 and 2019

Cited by 13 publications

References 40 publications

Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019

Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019

Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial

Health‐related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year

Contact Info

Product

Resources

About